Literature DB >> 27819227

Diminished but not dead: chemotherapy for the treatment of NSCLC.

Roy S Herbst1, Mario Sznol2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27819227     DOI： 10.1016/S1470-2045(16)30524-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

Review 1.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

Review 2.  Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.

Authors:  Sohita Dhillon; Yahiya Y Syed
Journal:  Target Oncol       Date:  2019-12       Impact factor: 4.493

Review 3.  Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Authors:  Deborah B Doroshow; Miguel F Sanmamed; Katherine Hastings; Katerina Politi; David L Rimm; Lieping Chen; Ignacio Melero; Kurt A Schalper; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

Review 4.  Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Authors:  Jamie E Chaft; Andreas Rimner; Walter Weder; Christopher G Azzoli; Mark G Kris; Tina Cascone
Journal:  Nat Rev Clin Oncol       Date:  2021-04-28       Impact factor: 65.011

5.  The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.

Authors:  Helmy M Guirgis
Journal:  J Immunother Cancer       Date:  2018-02-20       Impact factor: 13.751

6.  Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.

Authors:  Shunichi Sudo; Hiroshi Kajiya; Shinji Okano; Mina Sasaki; Yuri Katsumata; Jun Ohno; Tetsuro Ikebe; Akimitsu Hiraki; Koji Okabe
Journal:  Cancer Sci       Date:  2020-02-29       Impact factor: 6.716

Review 7.  Expert consensus on perioperative treatment for non-small cell lung cancer.

Authors:  Jianchun Duan; Fengwei Tan; Jie Wang; Shugeng Gao; Nan Bi; Chun Chen; Ke-Neng Chen; Ying Cheng; Qian Chu; Di Ge; Jie Hu; Yunchao Huang; Tao Jiang; Hao Long; You Lu; Meiqi Shi; Jialei Wang; Qiming Wang; Fan Yang; Nong Yang; Yu Yao; Jianming Ying; Caicun Zhou; Qing Zhou; Qinghua Zhou; Stefano Bongiolatti; Alessandro Brunelli; Alfonso Fiorelli; Elisa Gobbini; Cesare Gridelli; Thomas John; Jae Jun Kim; Steven H Lin; Giulio Metro; Fabrizio Minervini; Nuria M Novoa; Dwight H Owen; Maria Rodriguez; Ichiro Sakanoue; Marco Scarci; Kenichi Suda; Fabrizio Tabbò; Terence Chi Chun Tam; Masanori Tsuchida; Junji Uchino; Luca Voltolini
Journal:  Transl Lung Cancer Res       Date:  2022-07

8.  In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer.

Authors:  Poorva Bindal; Page Widick; Daniel B Costa; Deepa Rangachari
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.